
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 224 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Severity of obstructive airway disease and risk of osteoporotic fracture”, Eur Respir J, vol. 25, pp. 879-84, 2005.
, “A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis”, Neurology, vol. 79, pp. 922-8, 2012.
, “A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids”, Qjm, vol. 98, pp. 191-8, 2005.
, “Smoke-free legislation and the incidence of paediatric respiratory infections and wheezing/asthma: interrupted time series analyses in the four UK nations”, Sci Rep, vol. 5, p. 15246, 2015.
, “Statin treatment and reduced risk of pneumonia in patients with diabetes”, Thorax, vol. 61, pp. 957-61, 2006.
, “The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 359-66, 2000.
, “Use of alpha-blockers and the risk of hip/femur fractures”, J Intern Med, vol. 254, pp. 548-54, 2003.
, “Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands”, Calcif Tissue Int, vol. 80, pp. 69-75, 2007.
, “Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture”, Bone, vol. 68, pp. 124-30, 2014.
, “Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study”, Diabetes Obes Metab, vol. 19, pp. 401-411, 2017.
, “Use of incretin agents and risk of pancreatic cancer: a population-based cohort study”, Diabetes Obes Metab, vol. 18, pp. 258-65, 2016.
, “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
, “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
, “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
, “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
, “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
, “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
, “Use of statins is associated with an increased risk of rheumatoid arthritis”, Ann Rheum Dis, vol. 71, pp. 648-54, 2012.
, “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
, “What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
,